These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 3025219)

  • 21. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
    Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
    Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
    Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
    Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
    Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH
    Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
    Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide.
    Hwang JL; Shyy SH; Chen AY; Juan CC; Whang-Peng J
    Cancer Res; 1989 Feb; 49(4):958-62. PubMed ID: 2536295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.
    Webb CD; Latham MD; Lock RB; Sullivan DM
    Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling.
    Escargueil AE; Plisov SY; Skladanowski A; Borgne A; Meijer L; Gorbsky GJ; Larsen AK
    FASEB J; 2001 Oct; 15(12):2288-90. PubMed ID: 11511510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of DNA topoisomerases in chronic proliferative kidney disease.
    Ivanova LV; Rudolph P; Kellner U; Jürgensen A; Tareeva IE; Alm P; Proppe D
    Kidney Int; 2000 Oct; 58(4):1603-12. PubMed ID: 11012894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The specificity of human lymphocyte nucleolar DNA long-range fragmentation by endogenous topoisomerase II and exogenous Bal 31 nuclease depends on cell proliferation status.
    Iarovaia OV; Lagarkova MA; Razin SV
    Biochemistry; 1995 Mar; 34(12):4133-8. PubMed ID: 7696277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
    Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D
    Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
    Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
    Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defective DNA topoisomerase II in ataxia-telangiectasia cells.
    Lavin MF; Singh SP
    Acta Biol Hung; 1990; 41(1-3):125-35. PubMed ID: 1965559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA topoisomerase II-dependent control of the cell cycle progression in root meristems of Allium cepa.
    Zabka A; Polit JT; Bernasińska J; Maszewski J
    Cell Biol Int; 2014 Mar; 38(3):355-67. PubMed ID: 24302674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J; Catapano CV; Fernandes DJ
    Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of DNA topoisomerases during cellular differentiation.
    Bodley AL; Wu HY; Liu LF
    NCI Monogr; 1987; (4):31-5. PubMed ID: 2819728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues.
    Holden JA; Rolfson DH; Wittwer CT
    Biochemistry; 1990 Feb; 29(8):2127-34. PubMed ID: 2158345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.